|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BRAF mutations have been found in a high percentage of melanoma cell lines and metastases; however, only a few studies with a limited number of specimens have focused on primary melanomas.
|
15140228 |
2004 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Extended BRAF testing using PCR for 9 mutations and VE1 immunohistochemistry for BRAF V600E detection on 95 lesions including 40 primary melanomas with their matched metastases (n = 42), recurrences (n = 9) and second primaries (n = 4) was performed.Nine patients had multiple metastases.
|
25236573 |
2014 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Because we were interested in diagnostic and therapeutic consequences, we studied the KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary CRCs; in addition, we studied their available metastases.
|
21704278 |
2011 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We found BRAF mutations in 21 of 29 metastases.
|
23555633 |
2013 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BRAF and RAS mutational status was tested on primary and/or metastases by means of pyrosequencing and mass spectrometry genotyping assay.
|
25942399 |
2015 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BRAF(V599E) tended to be associated, although not significantly, with a greater volume and extension of the tumour and with lymph-nodal metastases at surgery.
|
15272920 |
2004 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We examined the pattern of BRAF mutations in noncontiguous tumor foci and node metastases from 69 patients affected by multicentric PTC.
|
17535994 |
2007 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The objective was to evaluate DNA mutations of KRAS, BRAF, and PIK3CA and their clinicopathological correlations with colorectal cancer (CRC) and to identify their contribution to distant metastases in CRC.
|
24861917 |
2014 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
KRAS mutations were associated with lung-only metastases (P = 2.3 × 10(-4)), BRAF mutations with peritoneal (P = 9.2 × 10(-4)) and nodal-only (P = 3.7 × 10(-5)) metastases, and MSI (BRAF(WT)) with nodal-only metastases (P = 2.9 × 10(-4)).
|
23741067 |
2013 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
BRAF status was concordant in all primary tumors and matched metastases (79 wild-type pairs and two mutant pairs).
|
20635392 |
2011 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
A certain degree of discordance between primary tumors and corresponding metastases was demonstrated for all examined biomarkers except BRAF mutations.
|
22936063 |
2013 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BRAF mutations and EGFR intron 1 CA repeat polymorphisms were concordant between primary tumors and paired metastases.
|
21340604 |
2011 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The BRAF(V600E) mutation was detected in 88 of the tumors examined, with significant differences between groups with and without lymph node (LN) metastases; the mean age of patients with BRAF(V600E) mutation was significantly higher than that of patients without mutations.
|
17685465 |
2007 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients with BRAF-mutated mCRC presented more frequently with peritoneal involvement (26% vs 14%; P < 0.01) and less frequently with liver-limited metastases (41% vs 63%; P < .01).
|
24737664 |
2014 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study demonstrates that black compared to nonblack metastases have a greater degree of cystic degeneration and hemosiderin deposition leading to discoloration, and a trend toward an increased incidence in BRAF V600E mutations.
|
23343222 |
2013 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BRAF mutation was strongly associated with peritoneal metastases (relative risk = 1.8, p < .001) with lower incidence of lung (RR = 0.3, p = .004) and liver (RR = 0.7, p = .005) limited metastases.
|
30035653 |
2018 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The effect of BRAF-I on IFNAR1 expression was assessed in three melanoma cell lines and in four biopsies of BRAF(V600E) metastases.
|
26851802 |
2016 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We describe the occurrence of RRR in three melanoma patients who had undergone radiotherapy for metastases followed by systemic treatment with the BRAF inhibitor vemurafenib.
|
24743051 |
2014 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
|
22105775 |
2012 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BRAF mutant tumors were also associated with nodal metastases (OR=1.9 P = 0.004), despite being thinner at diagnosis than BRAF WT (median 1.2 mm versus 1.6 mm, P < 0.001).
|
25043693 |
2014 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BRAF(V600E) mutation is identified in a subset of cutaneous metastases from PTC.
|
17387744 |
2007 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A BRAF mutation was found in 21 of 53 cases (40 %), significantly associated with tumor thickness and presence of metastases in the sentinel lymph node.
|
26055532 |
2015 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BRAF mutations were found in 84 patients (44.9%) and 144 tumour samples (48%) with BRAF mutations in 45.5% of primary tumours and 51.3% of metastases, respectively.
|
24196789 |
2013 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The robustness of 24 candidate reference genes was evaluated across 80 formalin-fixed paraffin-embedded melanomas of different thickness, -/+ ulceration, -/+ reported cases of metastases and of different BRAF mutation status using quantitative real-time PCR.
|
31567589 |
2020 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BRAF mutation cannot be regarded as a reliable marker of node metastases in patients with PTC.
|
24839220 |
2014 |